AMP executives are the focus of the Australian Securities and Investments Commission’s investigation of the wealth management firm’s fees for no service scandal, a court heard Friday.
Acciona mulls settlement with NSW Government in light rail dispute
AMP contractor pleads guilty to stealing customer data
Wyeth defends validity of patents in trial over best-selling Prevnar 13 vaccine
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.